Hemostemix Inc. (HMTXF)
USD 0.07
(4.99%)
USD 0.07
(4.99%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 2.33 Million CAD | -49.03% |
| 2022 | 4.57 Million CAD | -31.22% |
| 2021 | 6.65 Million CAD | -10.86% |
| 2020 | 7.46 Million CAD | 58.99% |
| 2019 | 4.69 Million CAD | -26.89% |
| 2018 | 6.42 Million CAD | 128.56% |
| 2017 | 2.81 Million CAD | -24.28% |
| 2016 | 3.71 Million CAD | -6.79% |
| 2015 | 3.98 Million CAD | -7.25% |
| 2014 | 4.29 Million CAD | 180.1% |
| 2013 | 1.53 Million CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 364.06 Thousand CAD | 11.78% |
| 2024 Q1 | 325.71 Thousand CAD | 187.73% |
| 2023 Q4 | 113.2 Thousand CAD | -72.76% |
| 2023 FY | 2.15 Million CAD | -52.89% |
| 2023 Q1 | 1.13 Million CAD | 81.13% |
| 2023 Q2 | 493.25 Thousand CAD | -56.4% |
| 2023 Q3 | 415.54 Thousand CAD | -15.75% |
| 2022 Q4 | 624.58 Thousand CAD | -39.87% |
| 2022 Q2 | 1.58 Million CAD | 18.78% |
| 2022 Q1 | 1.33 Million CAD | -62.29% |
| 2022 FY | 4.57 Million CAD | -31.22% |
| 2022 Q3 | 1.03 Million CAD | -34.45% |
| 2021 Q4 | 3.53 Million CAD | 164.17% |
| 2021 Q2 | 1.11 Million CAD | 67.84% |
| 2021 Q3 | 1.33 Million CAD | 20.13% |
| 2021 FY | 6.65 Million CAD | -10.86% |
| 2021 Q1 | 664.2 Thousand CAD | -82.81% |
| 2020 Q4 | 3.86 Million CAD | 165.75% |
| 2020 FY | 7.46 Million CAD | 58.99% |
| 2020 Q3 | 1.45 Million CAD | -28.99% |
| 2020 Q2 | 2.04 Million CAD | 1892.98% |
| 2020 Q1 | 102.7 Thousand CAD | -81.45% |
| 2019 Q4 | 553.71 Thousand CAD | -57.28% |
| 2019 FY | 4.69 Million CAD | -26.89% |
| 2019 Q1 | 1.53 Million CAD | -17.29% |
| 2019 Q2 | 1.3 Million CAD | -15.06% |
| 2019 Q3 | 1.29 Million CAD | -0.85% |
| 2018 Q2 | 1.73 Million CAD | 44.16% |
| 2018 Q1 | 1.2 Million CAD | 472.3% |
| 2018 FY | 6.42 Million CAD | 128.56% |
| 2018 Q4 | 1.86 Million CAD | 14.33% |
| 2018 Q3 | 1.62 Million CAD | -6.08% |
| 2017 FY | 2.81 Million CAD | -24.28% |
| 2017 Q1 | 536.71 Thousand CAD | -35.41% |
| 2017 Q4 | -322.86 Thousand CAD | -112.44% |
| 2017 Q2 | 474.07 Thousand CAD | -11.67% |
| 2017 Q3 | 2.59 Million CAD | 447.67% |
| 2016 Q4 | 831.01 Thousand CAD | -47.73% |
| 2016 FY | 3.71 Million CAD | -6.79% |
| 2016 Q3 | 1.58 Million CAD | 153.3% |
| 2016 Q2 | 627.59 Thousand CAD | -5.33% |
| 2016 Q1 | 662.94 Thousand CAD | -42.78% |
| 2015 Q1 | 876.34 Thousand CAD | -59.47% |
| 2015 FY | 3.98 Million CAD | -7.25% |
| 2015 Q4 | 1.15 Million CAD | 17.23% |
| 2015 Q3 | 988.34 Thousand CAD | 3.13% |
| 2015 Q2 | 958.35 Thousand CAD | 9.36% |
| 2014 FY | 4.29 Million CAD | 180.1% |
| 2014 Q4 | 2.16 Million CAD | 159.34% |
| 2014 Q3 | 833.7 Thousand CAD | 2142.1% |
| 2014 Q2 | 37.18 Thousand CAD | 290.63% |
| 2014 Q1 | 9519.00 CAD | -40.39% |
| 2013 Q2 | 35.39 Thousand CAD | -31.73% |
| 2013 FY | 1.53 Million CAD | 0.0% |
| 2013 Q3 | 16.76 Thousand CAD | -52.62% |
| 2013 Q4 | 15.97 Thousand CAD | -4.76% |
| 2013 Q1 | 51.84 Thousand CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 10.86 Million USD | 78.528% |
| Skye Bioscience, Inc. | 13.54 Million USD | 82.777% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 93.737% |
| Nascent Biotech, Inc. | 2.22 Million USD | -4.639% |
| Qrons Inc. | 643.67 Thousand USD | -262.498% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 89.844% |
| CSL Limited | 3.44 Billion USD | 99.932% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 92.105% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 53.723% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -152.657% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 95.938% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -461.597% |
| Rebus Holdings, Inc. | 664 Thousand USD | -251.403% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -74.724% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -498.953% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 85.426% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 97.311% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 52.555% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -791.511% |
| SQZ Biotechnologies Company | 85.61 Million USD | 97.275% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 19.989% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -55.358% |
| Mesoblast Limited | 5.9 Million USD | 60.466% |
| Marizyme, Inc. | 19.23 Million USD | 87.872% |
| Genus plc | 147.7 Million USD | 98.42% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 73.422% |
| Pharming Group N.V. | 225.49 Million USD | 98.965% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -13.892% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -73.928% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 72.019% |
| ContraFect Corporation | 56.88 Million USD | 95.898% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 47.074% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -57.79% |
| IMV Inc. | 37.7 Million USD | 93.812% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 16.379% |
| MultiCell Technologies, Inc. | 567.42 USD | -411115.149% |
| ONE Bio Corp. | 6.44 Million USD | 63.79% |
| Accustem Sciences Inc. | 3.74 Million USD | 37.719% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 97.285% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -338.625% |
| Q BioMed Inc. | 3.43 Million USD | 32.104% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 90.559% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 11.197% |
| Biomind Labs Inc. | 994.18 Thousand USD | -134.697% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 97.651% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -32.599% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 65.268% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -25.153% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 9433.268% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -27.15% |
| GB Sciences, Inc. | 1.42 Million USD | -64.259% |
| Alpha Cognition Inc. | 9.7 Million USD | 75.959% |
| HST Global, Inc. | 140.9 Thousand USD | -1555.927% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -107.423% |
| Halberd Corporation | 74.84 Thousand USD | -3017.657% |
| Enzolytics Inc. | 2.17 Million USD | -7.057% |
| Agentix Corp. | 1.37 Million USD | -70.097% |
| Resverlogix Corp. | 12.71 Million USD | 81.645% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 36.086% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.848% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -123.498% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 2.978% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -47.739% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 31.473% |
| AVAX Technologies, Inc. | 7.31 Million USD | 68.082% |
| Zenith Capital Corp. | 8.94 Million USD | 73.909% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.717% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -13293.703% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 4.969% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -1260.463% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -21.47% |
| Kadimastem Ltd | 2.41 Million USD | 3.186% |
| Helix BioMedix, Inc. | 1.97 Million USD | -18.32% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1185.68% |
| LadRx Corporation | 3.81 Million USD | 38.787% |
| Cell Source, Inc. | 4.32 Million USD | 46.055% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -152.657% |
| NovAccess Global Inc. | 2.46 Million USD | 5.41% |
| Affymax, Inc. | 39.38 Million USD | 94.076% |
| Itoco Inc. | 919.14 Thousand USD | -153.858% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 44.948% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -108.518% |
| Mobile Lads Corp. | 554.54 Thousand USD | -320.762% |
| CytoDyn Inc. | 18.05 Million USD | 87.079% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -9170.599% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -960.223% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -64.342% |
| SYBLEU INC | 160.87 Thousand USD | -1350.382% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -28.464% |
| International Stem Cell Corporation | 5.27 Million USD | 55.733% |
| Bioxytran, Inc. | 3.82 Million USD | 38.921% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -4332.425% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -11369.877% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 93.566% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -44.21% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -217.098% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 24.998% |
| Neutra Corp. | 243.82 Thousand USD | -856.98% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 86.634% |
| PureTech Health plc | 144.59 Million USD | 98.386% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 88.612% |
| IXICO plc | 4.7 Million USD | 50.429% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 73.476% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.018% |
| CSL Limited | 3.89 Billion USD | 99.94% |
| Cellectis S.A. | 97.32 Million USD | 97.602% |